All lobbying filings

CGCN Group, LLC

CGCN Group, LLC filed a Q3 report for Fresenius Kabi USA, LLC on October 20, 2025, reporting $30,000 in lobbying income.

Lobbying for Fresenius Kabi USA, LLC · Healthcare company

As filed: CGCN GROUP, LLC for FRESENIUS KABI USA, LLC.

All filings by CGCN Group, LLC · Everything Fresenius Kabi USA, LLC has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 20, 2025

Income

$30,000

What the client paid this registrant for the period.

Client based in

Illinois

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 4

Trade (domestic/foreign)

Sec. 232 investigation on pharmaceutical sector, tariffs, Buy America policies, Most Favored Nations Executive Order, reciprocal tariffs, essential medicines drug shortages related to trade agreements.

Manufacturing

Buy America legislation, tariffs, tax incentives, regulatory barriers to generic and biosimilar launches, patent waivers.

Tariff (miscellaneous tariff bills)

Section 232 investigation into pharmaceuticals and unfair trade practices.

Taxation/Internal Revenue Code

U.S. manufacturing incentives.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.